| Ytd | 47.41% | |
| 1y | 70.01% |
| Open | 136.16 | Prev Close | 136.55 | Low | 126.39 | High | 136.56 | Mkt Cap | 8.33B |
| Vol | 886.81K | Avg Vol | 630.47K | EPS | 1.03 | P/E | 125.00 | Forward P/E | -840.90 |
| Beta | 1.52 | Short Ratio | 13.63 | Inst. Own | 119.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 145.74 | 200-d Avg | 113.56 | 1yr Est | 178.21 |
PTGX News
Genelux (NASDAQ: GNLX - Get Free Report) and Protagonist Therapeutics (NASDAQ: PTGX - Get Free Repor
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growin
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.28% o
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a B
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Out
Protagonist Therapeutics (NASDAQ:PTGX) has outperformed the market over the past 10 years by 6.99% o
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that its Board of Directors has authori
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) wit
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperfo
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these s
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral t
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $2.29 per share which beat the
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w
Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that
Citizens analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and
Protagonist Therapeutics (NASDAQ:PTGX) reported quarterly earnings of $0.05 per share which beat the
By exercising its opt-out right during the contractual opt-out period, Protagonist becomes eligible
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) w
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
Clear Street analyst Kaveri Pohlman maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy a
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and
Leerink Partners analyst Faisal Khurshid maintains Protagonist Therapeutics (NASDAQ:PTGX) with a
Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and r
Barclays analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight
FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competiti
Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Pat
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) jumped 99% to $1.3195 after the company announ
On Tuesday, 951 companies hit new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
On Wednesday, 216 stocks hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched
Gainers MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) shares surged 73.4% to close at $12.80
Before 10 a.m. ET on Monday, 201 companies set new 52-week highs.